What Is Melanotan II?

1. How does Melanotan II work?

Your body uses α-MSH as a signaling molecule. Melanotan II is a modified peptide designed to activate the same receptor family. Its ring-shaped structure is why researchers call it a cyclic heptapeptide: “hepta” means seven.

MC1 receptors on pigment-producing skin cells, called melanocytes, participate in melanin production. Melanocortin signaling in the nervous system also influences appetite and sexual responses. A substance acting across this family can therefore change more than skin color.

Tomassi and colleagues’ 2022 receptor experiments used Melanotan II as the starting molecule to develop more selective compounds. Their work describes MT2 as a potent, nonselective agonist. “Agonist” means it activates a receptor; “nonselective” means it acts at multiple receptor subtypes. Receptor potency measures laboratory activity, not how safely someone can use a tanning product.

2. What do the human studies show?

These three early trials are the main human efficacy studies discussed here. The results below come from their published abstracts, which provide sample sizes, designs and measured outcomes.

In a crossover study, participants receive both active treatment and placebo at different times. That helps researchers detect a short-term drug effect in a small group. It does little to answer what happens after repeated summer use or years of exposure.

The studies measured different things. Pigmentation, erection rigidity and sexual desire should stay separate when evaluating a claim. None is a measurement of skin-cancer prevention, testosterone production or sustained fat loss.

3. Tanning results, timing and UV exposure

The tanning pilot provides evidence that MT2 can increase human pigmentation. Its three participants cannot predict the shade, evenness or speed of a tan across different skin types. The measurement one week after treatment also should not become a promise that everyone will see results by a particular day.

Before-and-after photos leave several variables unresolved: sunlight, tanning beds, camera exposure, lighting and other tanning products. If someone starts MT2 and changes UV exposure simultaneously, the photo cannot tell you how much of the change came from the peptide.

Nor does darker skin establish protection from UV injury. The TGA warns that melanotan-induced pigmentation does not provide protection comparable to suitable sunscreen. There is no validated MT2 regimen that makes sunbeds safe or replaces sunscreen, clothing and shade. A visible tan cannot tell you how much DNA damage occurred.

4. Melanotan II nasal spray vs injections

The early human trials used subcutaneous injections. They did not test the nasal products sold today or compare the two routes. Reliable human evidence does not establish that a nasal spray produces equivalent tanning with fewer systemic side effects.

A nasal product still needs to deliver an active substance across a biological barrier. Its bioavailability, concentration and spray output determine exposure. Counting sprays cannot resolve those unknowns.

What the TGA found in August 2026

The TGA tested five seized nasal spray bottles labeled “Pure Tans Triple Strength 30 MG.” Based on the labeled 20 mL volume, estimated MT2 content ranged from 22 to 54 mg per bottle.

Compared with the claimed 30 mg, those estimates are approximately 27% below to 80% above the label. That calculation describes these five bottles, not the whole market. It demonstrates why recording a label dose precisely can still produce an inaccurate exposure record.

Avoiding a needle removes needle-related risks. It does not verify the contents or eliminate the pharmacological effects of an absorbed peptide. A supplier’s purity percentage also cannot establish the accuracy or sterility of a finished injectable product.

5. Libido, erections and fat-loss claims

The erectile-function trials support a real short-term effect in some men with erectile dysfunction. The 2000 study also found higher reported sexual desire after MT2 than placebo. That does not demonstrate an increase in testosterone: desire, erection and hormone levels are different outcomes.

In Chen and colleagues’ mouse experiment, MT2 reduced food intake and increased metabolic rate in ordinary mice. Mice lacking functional MC4 receptors did not show those responses. This helps identify the pathway; it supplies no human fat-loss percentage.

The 1998 human trial reported reduced appetite among transient side effects. It was not a weight-loss trial. Eating less during nausea cannot establish sustained fat loss, better body composition or acceptable tolerability over months.

MT2 does not act as a GLP-1 receptor agonist. The studies above offer no evidence that adding it to semaglutide or tirzepatide improves outcomes. Starting several compounds together also makes it harder to identify the cause of nausea or a change in appetite.

6. Melanotan II side effects and serious reactions

Early trials reported nausea, yawning, stretching, reduced appetite and spontaneous erections; the tanning pilot also reported sleepiness and fatigue. The samples were too small to give dependable frequencies for most effects in ordinary use. Severe nausea after 4 of 19 injections in the 2000 trial is an injection-level result, not an estimate that four in nineteen users will experience it.

Some reports describe much more serious events. Mallory, Lopategui and Cordon documented a 55-year-old man who arrived with a painful erection lasting 30 hours after MT2 use. He required surgery and reported erectile dysfunction at follow-up. He had used melanotan in previous years, so prior tolerance did not prevent this episode.

An erection lasting four hours or longer needs emergency care. Do not wait for a presumed peptide half-life to pass.

Peters and colleagues reported a renal infarction, an interruption of blood supply to part of the kidney, possibly associated with MT2. The FDA safety assessment also cites reports of priapism, neurological illness and a syndrome of excessive sympathetic nervous system stimulation, alongside potential immune reactions from peptide aggregation or impurities.

These reports identify events requiring attention. Without knowing how many people used verified products, they cannot tell us how often those events occur or isolate the peptide from every other possible cause.

7. Does Melanotan II cause melanoma?

Melanoma has been diagnosed after melanotan exposure. The available reports do not establish that MT2 caused those cancers or measure an added risk. They also cannot establish that repeated exposure is safe.

A 2026 report by Vadner and Smith describes a 49-year-old man with five melanomas in situ, meaning the cancers were confined to the skin’s outer layer. He reported using MT2 followed by MT1, approximately 12 recent tanning-bed sessions, and rapid darkening of existing moles. He also had prior UV exposure, many atypical moles and a family history of melanoma.

The authors explicitly raise the possibility that cancers were already present and became more noticeable after pigmentation changed. The short interval between exposure and diagnosis cannot prove that melanotan created five new cancers in weeks. Multiple exposures and the absence of baseline skin examinations prevent separating their contributions.

A changing mole still needs assessment, even when its darkening seems connected to a tanning peptide. A new or evolving lesion, irregular color or border, or bleeding should prompt a clinician or dermatologist review. Photographs can document change; they cannot rule out melanoma.

8. Melanotan I vs II vs PT-141

Similar names cause different evidence to get mixed together. Approval of one melanocortin drug does not validate another molecule or an online vial bearing a related name.

SCENESSE’s evidence concerns a defined implant and a specific disease. It does not establish that an internet product labeled MT1 is equivalent or that either melanotan is approved for cosmetic tanning.

VYLEESI’s label excludes use for sexual-performance enhancement and treatment in men. PT-141 and MT2 cannot be substituted on the assumption that shared receptor activity means shared dosing, effects or safety.

9. Dosage, cycles and half-life

There is no approved MT2 cosmetic dose, loading phase or maintenance cycle. A dose chosen for a small supervised experiment does not establish the balance of benefit and harm for recreational use. Product-strength uncertainty adds another problem before absorption is even considered.

The human trials above do not establish a dependable plasma half-life for retail nasal or injectable products. A pigmentation change can outlast the signal that triggered it. Likewise, the duration of an erection is not a blood-clearance measurement. Treating either as a half-life produces an unsupported redosing schedule.

If a peptide half-life model asks for a number, entering an assumed value only generates a curve from that assumption. It cannot determine when MT2 has cleared or another exposure would be safe.

10. FDA status and the planned compounding review

Melanotan II has no FDA-approved use as of September 21, 2026. FDA’s enforcement record identifies it as an unapproved drug, and the agency continues to list specific safety concerns.

FDA has announced an advisory committee discussion before the end of February 2027 about possible inclusion on the 503A bulk-substances list. That is a compounding-policy process. The committee’s recommendations are nonbinding, and the announcement does not approve a finished drug or a tanning protocol.

Australia’s August 2026 advisory states that no MT2 products are included in its therapeutic-goods register or approved for supply. The TGA advises consumers to stop using MT2 tanning products and consult a healthcare practitioner about concerns.

If you are discussing previous use with a clinician, bring the product label, exposure dates, route, other drugs and any skin photographs. A peptide log can preserve that history. Record the amount as the labeled amount when the contents were not independently verified, and include UV exposure and symptom onset alongside it.

11. Melanotan II FAQ

• Is Melanotan 2 the same as Melanotan II or MT2?

  Yes. Those names usually refer to the same experimental peptide. Melanotan I, also called afamelanotide, and PT-141, also called bremelanotide, are different compounds.

• Does Melanotan II work for tanning?

  A small human pilot demonstrated increased pigmentation, but it enrolled only three men. That evidence does not establish a predictable cosmetic result, safe long-term use or protection from skin cancer.

• How long does Melanotan II take to work?

  The 1996 pilot documented increased pigmentation in two participants one week after the dosing period ended. It does not establish a universal onset time or how long a tan from a retail product will last.

• Is Melanotan II nasal spray safer than injections?

  Reliable human comparisons have not established that. A nasal spray avoids injection-related needle risks but still exposes the body to an active drug, and product strength can be inaccurate.

• Does Melanotan II cause melanoma?

  Cases have been reported after use, but causation remains unresolved. UV exposure, pre-existing lesions and other factors complicate interpretation. Existing evidence cannot quantify the added risk or establish long-term cancer safety.

• Does Melanotan II increase libido or testosterone?

  Small studies in men with erectile dysfunction found erections and increased reported sexual desire. Those findings do not establish a testosterone increase or reliable sexual benefits for healthy users.

• Does Melanotan II burn fat?

  Mouse experiments and reports of reduced appetite do not establish sustained fat loss in humans. There is no validated human weight-loss protocol or established benefit from adding it to a GLP-1 medication.

• What is a safe Melanotan II dose or cycle?

  No approved cosmetic dose, loading phase or maintenance cycle exists. Small supervised studies cannot validate online self-use schedules, especially when product contents and absorption are uncertain.

• What is the half-life of Melanotan II?

  The human studies discussed here do not establish a dependable half-life for retail injectable or nasal products. Duration of pigmentation or erections cannot be used to calculate blood clearance or a safe redosing interval.

• Is Melanotan II FDA-approved?

  No, as of September 21, 2026. FDA plans an advisory discussion of its possible use in compounding before the end of February 2027. That discussion is separate from approval of a finished medicine.

12. Sources